Research programme: site specific immunomodulators - Qu Biologics

Alternative Names: QBECP; QBSAU; SSI - Qu Biologics

Latest Information Update: 02 Oct 2015

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Qu Biologics
Developer Geisel School of Medicine; McMaster University; Qu Biologics
Class Bacterial antigens; Cancer vaccines
Mechanism of Action Immunomodulators; Macrophage modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Cancer; Crohn's disease; Inflammation; Inflammatory bowel diseases; Lung cancer; Malignant melanoma; Rheumatoid arthritis

Most Recent Events

18 Aug 2015 Qu Biologics has patent protection for site specific modulators in USA
11 May 2015 Qu Biologics has patent protection for site specific immunomodulators in Europe
31 Mar 2015 Qu Biologics has patent protection for site specific immunomodulators in USA

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.